Findings

What do systematic reviews say?

4 questions · 8 findings · 2 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 6 · 75%Very low 0 · 0%Low 1 · 12.5%Moderate 0 · 0%High 1 · 12.5%

Silver diamine fluoride (SDF) vs Not applicable (single-arm safety outcome)

Serious adverse events · Children and older adults treated with SDF for carious lesions

No serious adverse events (e.g., allergic reactions or toxicity) were reported for SDF across the reviews (ungraded).

1 finding from 1 review

Silver diamine fluoride for managing carious lesions: an umbrella review. 2019 All outcomes
No serious adverse events, such as allergic reactions or toxicity, were reported. A metallic taste or burning sensation was not reported in any of the studies.
Studies not reported
GRADE not reported

Silver diamine fluoride (SDF) vs Not applicable (single-arm safety outcome)

Adverse events: black staining of arrested lesions · Children and older adults treated with SDF for carious lesions

Black staining of arrested lesions was the main adverse event of SDF (reported by seven reviews); it was generally acceptable to patients (ungraded).

1 finding from 1 review

Silver diamine fluoride for managing carious lesions: an umbrella review. 2019 All outcomes
Eight systematic reviews reported adverse events; seven reported black staining of arrested carious lesions. Older adults rarely complained; discoloration was acceptable in children, concerning 7% of participants in…
Studies not reported
GRADE not reported

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).

3 findings from 1 review

The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type A
SMD -0.80 [-1.25, -0.36]
4 studies · 88 participants
GRADE not reported
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type B
SMD -1.11 [-1.48, -0.74]
5 studies · 136 participants
GRADE not reported
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia)
SMD -0.98 [-1.27, -0.70]
9 studies · 224 participants
High

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).

3 findings from 1 review

The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type A
RD 0.10 [0.00, 0.21]
5 studies · 117 participants
GRADE not reported
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia)
RD 0.15 [0.05, 0.24]
10 studies · 249 participants
Low
The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomes
Approximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type B
RD 0.18 [0.04, 0.33]
5 studies · 132 participants
GRADE not reported